Apigenin: Natural Sleep and Calming Compound
Apigenin binds the benzodiazepine site, inhibits the enzyme that consumes NAD+, and has almost no human trial evidence for either.
The Short Answer
Apigenin is a flavone found in chamomile, parsley, celery and several other plants, which binds the benzodiazepine site of the GABA-A receptor as a low-affinity partial agonist and separately inhibits CD38, the enzyme that consumes NAD+ and whose activity rises with age. Those two mechanisms explain why it appears in both sleep formulas and NAD+ stacks. The human evidence supports neither directly: chamomile extract has modest trial evidence for anxiety and sleep quality, isolated apigenin has essentially no human trial data at supplemental doses, and its bioavailability is poor enough that achieving the concentrations used in cell studies is unlikely.
The Two Mechanisms
GABA-A modulation. Apigenin binds the benzodiazepine binding site on the GABA-A receptor with modest affinity, acting as a partial agonist or, in some assays, a weak antagonist depending on subunit composition. In animal work it produces mild sedative and anxiolytic effects at doses that do not produce the motor impairment or amnesia characteristic of benzodiazepines. This is the pharmacological basis for chamomile's traditional use.
CD38 inhibition. CD38 is a major consumer of NAD+, and its activity increases with age and with inflammatory signalling, making it a substantial contributor to the age-related decline in NAD+. Apigenin inhibits CD38 in enzymatic assays and in cell work, and in mice apigenin administration raised NAD+ concentrations in liver and muscle and improved metabolic markers.
The second mechanism is why apigenin appears in NAD+ products alongside precursors: the idea is to add substrate while reducing consumption. It is mechanistically coherent, which is not the same as demonstrated.
The Evidence Gap
Almost all the interesting work on apigenin is in cells and animals, and the gap to human evidence is the central fact.
What exists in humans. Chamomile extract, standardised to apigenin content, has been trialled for generalised anxiety with modest reductions in symptom scores, and for sleep quality in older adults and postpartum women, with small improvements in subjective measures. These trials used chamomile extract, which contains many compounds, not isolated apigenin.
What does not exist. Any human trial of isolated apigenin for sleep, anxiety, NAD+ concentrations or metabolic outcomes at supplemental doses. Any human dose-finding. Any human data on whether oral apigenin inhibits CD38 in vivo.
Why that matters more than usual. Apigenin's bioavailability is poor: it is poorly water soluble, extensively conjugated on first pass, and plasma concentrations after oral dosing sit in the low nanomolar range, while CD38 inhibition in enzymatic work occurs at micromolar concentrations. The gap is roughly a thousandfold. Unless tissue accumulation or metabolite activity closes it, the CD38 mechanism is unlikely to be operating at supplemental doses.
Dose and Practicalities
- 50 mg per day. The most common supplemental dose, chosen by convention rather than by trial.
- Chamomile extract standardised to 1.2 percent apigenin, 220 to 1,100 mg per day. The range used in the anxiety and sleep trials.
- Dietary intake. Parsley is exceptionally rich, followed by celery, chamomile tea and some herbs. Typical dietary intake is a few milligrams per day.
Absorption. Taking apigenin with fat improves absorption modestly. Phospholipid complexes report better exposure. None of this has been tested against an outcome.
Timing. Evening, for the sleep application. There is no basis for a specific time for the NAD+ application, since the mechanism is chronic rather than acute.
Safety and Interactions
Apigenin at dietary and typical supplemental doses is well tolerated, and chamomile has a long history of consumption.
Several considerations are worth naming, mostly theoretical.
- Cytochrome P450 inhibition. Apigenin inhibits several CYP enzymes in vitro, including CYP2C9 and CYP3A4, which is the standard flavonoid interaction concern and relevant to anyone on prescription medication.
- Sedative additivity. Given the GABA-A activity, additive effects with benzodiazepines, alcohol and other sedatives are plausible.
- Chamomile allergy. Chamomile is in the Asteraceae family, and cross-reactivity with ragweed and related allergens is documented, occasionally with serious reactions.
- Anticoagulant caution. Chamomile contains coumarin derivatives, and case reports describe bleeding events with warfarin.
- Oestrogenic activity in vitro. Reported for apigenin, which is a reason to raise it rather than a demonstrated clinical effect.
An Honest Assessment
Apigenin is a compound whose reputation rests almost entirely on mechanism, and whose mechanisms operate at concentrations oral dosing probably does not achieve.
For sleep, chamomile extract has the modest human evidence, and if the objective is a gentle calming effect before bed, chamomile tea or a standardised extract is the format with data behind it. Isolated apigenin at 50 milligrams is a reasonable thing to try and is not supported by trials.
For NAD+, the CD38 inhibition rationale is genuinely interesting and the bioavailability arithmetic argues against it working at supplemental doses. Anyone buying a NAD+ product because it contains apigenin should know they are paying for an unproven addition, and that reducing inflammatory load, which is what drives CD38 activity upward in the first place, addresses the same target with far better evidence.
The review trigger here is external: human pharmacokinetic and CD38 work would settle whether the mechanism is reachable, and it has not been done.
The AEONNN Perspective
Apigenin is the clearest case in this batch of a compound where the Pharmacokinetics layer contradicts the Mechanistic layer. The CD38 inhibition is real in enzymatic assays at micromolar concentrations; oral dosing produces low nanomolar plasma concentrations. AEONNN reports that gap rather than allowing an elegant mechanism to stand in for a demonstrated effect.
It maps to Sleep and Circadian Regulation and, through the NAD+ rationale, to Cellular Energy and Repair. In Stack Builder it is handled as an unproven addition rather than a functional slot, which matters when a member is paying a premium for a bundled NAD+ product whose price reflects ingredients with no human data.
The alternative route is also worth stating, because it is a cross-Pillar point: CD38 activity rises with inflammatory signalling, so lowering inflammatory load reduces NAD+ consumption through the same target with substantially better evidence than any flavonoid.
Pillar Matrix mapping
Database Matrix layers
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Pharmacokinetics Layer (HMDB, PubChem)
- Safety Layer (DrugBank, FAERS)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
Does apigenin help with sleep?
Chamomile extract standardised for apigenin has modest trial evidence for sleep quality and anxiety. Isolated apigenin has essentially no human trial data for sleep at supplemental doses.
How much apigenin should be taken?
50 mg per day is the common supplemental dose, chosen by convention rather than by trial. Chamomile trials used 220 to 1,100 mg per day of extract standardised to about 1.2 percent apigenin.
Does apigenin raise NAD+?
It inhibits CD38, a major NAD+ consumer, in enzymatic and cell work, and raised NAD+ in mice. Human evidence is absent, and the concentrations required are roughly a thousandfold above what oral dosing achieves in plasma.
Is apigenin worth adding to an NAD+ stack?
The rationale is coherent and unproven at achievable doses. Reducing inflammatory load lowers CD38 activity through the same target with far better evidence.
What foods contain apigenin?
Parsley is exceptionally rich, followed by celery, chamomile and several herbs. Typical dietary intake is a few milligrams per day.
Does apigenin interact with medication?
It inhibits several cytochrome P450 enzymes in vitro, including CYP2C9 and CYP3A4, and its GABA-A activity means additive sedation with benzodiazepines and alcohol is plausible. Chamomile also contains coumarin derivatives relevant to warfarin.
Is chamomile tea equivalent?
For the calming application, chamomile is the format with the human evidence, though tea delivers less than a standardised extract. For the NAD+ application, neither format has human data.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.